The biotech sector covers companies that apply biological and biochemical processes to develop products and services, primarily in healthcare, agriculture, and industrial applications. In the UK context, this typically means drug discovery firms, genomics businesses, diagnostics developers, and contract research organisations. Operators BF would write about include Oxford Biomedica, a cell and gene therapy manufacturer; Immunocore, a T-cell receptor therapy company; and Benchmark Holdings, which applies biotechnology to aquaculture and animal health.
BF tracks this sector because it sits at the intersection of deep science and commercial execution, and the gap between the two is where most operator-relevant decisions are made. Funding cycles, licensing deals, manufacturing partnerships, and regulatory milestones all shape how a biotech business is structured and run. For operators in adjacent sectors, such as contract manufacturing, laboratory services, or specialist recruitment, understanding biotech's commercial rhythms matters directly.
The open questions for the near term are substantial. How will the UK's post-Brexit regulatory relationship with the European Medicines Agency continue to affect approval timelines and market access? Can the domestic funding environment sustain early-stage companies through longer development cycles, or will more firms seek listings and capital abroad? And as AI-assisted drug discovery matures, what does that mean for the size and shape of the research teams that biotech businesses need to build?